Uniscan Instruments announces the new formation of Elisha Systems - a joint venture company 50% owned by Uniscan Instruments
Elisha Systems has been formed to exploit the intellectual property portfolio generated by Uniscan Instruments and several other researchers in the area of portable immuno-sensor technology.
This powerful new technology has applications in healthcare diagnostics as well as environmental analysis and general chemical analysis markets.
At the heart of Elisha technology is the labeless detection of antibody-antigen binding using direct electrochemical interrogation.
In short, simple immunosensing can be performed without labels and multiple wash steps with sensitivity directly comparable to standard Elisa techniques and non-specific binding is virtually eliminated using carefully designed electrodes.
The Elisha platform has been successfully demonstrated on ten different analytes so far, with many more in prospect.
Seven proteins, including PSA, S-100 protein, neuron specific enolase and myelin basic protein have been detected at the clinically relevant ranges.
